Integrating AI with care: FDA reveals focus areas for forthcoming guidance on AI products
Posted:
The FDA is focusing on integrating #AI with care, outlining key areas for forthcoming guidance on AI products. As AI technology expands, it's crucial to ensure safe implementation.
In Bold Insight latest blog, Stephanie Wiltman breaks down the FDA's focus areas and how they'll shape the future of AI in healthcare.
Obsessive-compulsive disorder (OCD) remains one of psychiatry’s most disabling conditions, affecting about 1-2% of the population. People with OCD have an 82% increase in all cause mortality compared with unnafected matched people from the general population, with suicide being a major contributor.…
The French pharma company Servier said Friday that it would buy Day One Biopharmaceuticals, the maker of a drug for childhood brain tumors, in a deal worth roughly $2.5 billion.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us